US Neurology Editorial Board member, Daniel Hanley (Johns Hopkins Medicine, Baltimore, Maryland, USA), provides his positive insights on MISTIE III, a clinical trial investigating the efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral hemorrhage evacuation, which failed to meet its primary endpoint of improved functional outcome at 1 year.
1. Could you tell us a little about the MISTIE procedure for the surgical removal of spontaneous intracerebral hemorrhage? (0:04)
2. What were the findings of the MISTIE III study? (1:14)
3. What lessons have been learned from MISTIE III and what will be the next steps in this research (3:12)
4. What are your hopes for the future of this research? (4:52)
Speaker disclosures: Daniel Hanley has nothing to disclose in relation to this video interview.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Philadelphia, USA, May 2019.
Share this Video
Related Videos In Stroke
Hariklia Proios, Stroke Alliance for Europe (SAFE): Presidential Update
The Stroke Alliance for Europe (SAFE) is a non-profit-making organisation that represents a range of patient groups from across Europe. Their mutual goal is to drive stroke prevention up the European political agenda and prevent the incidence of stroke through education. touchNEUROLOGY caught up with the SAFE President, Prof. Hariklia (Harriet) Proios, to discuss the […]
Martin Bretzner, ESOC 2022: Brain-age biomarkers to predict post-stroke recovery
Brain-age biomarkers can be used to predict post-stroke recovery. Dr Martin Bretzner (Lille Neuroscience & Cognition Research Centre, Lille University Hospital, Lille, France) discusses the results of a study using radiomics, an emerging image-quantifying technology to assess ‘brain-age’ biomarkers. The study investigates how relative brain age, rather than chronological age, can enhance stroke surveillance and […]
Miquel Lledós, ESOC 2022: The influence of gut microbiome on ischaemic stroke risk and outcome
The composition of the gut microbiome is a modifiable factor associated with the risk of ischaemic stroke and post-stroke neurological outcome. Dr Miquel Lledós (Stroke Pharmacogenomics and Genetics Laboratory, Sant Pau Research Institute, Barcelona, Spain) discusses the outcome of a study using faecal samples to demonstrate the influence of the gut microbiome on ischaemic stroke […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!